Abstract
We previously reported on the efficiency by which endogenous erythropoietin production corrects anemia after successful renal transplantation. Recent clinical experience with recombinant human erythropoietin in renal failure has demonstrated major benefit in correcting anemia with few adverse consequences. This article reviews our experience to date with recombinant human erythropoietin use in transplant recipients and explores the impact of therapy for the dialysis population awaiting transplantation. The issues of ongoing need for pretransplant blood transfusion, presensitization, organ transplant demand, therapeutic use of human recombinant erythropoietin for chronic rejection, and impact of an expanding, high-quality transplant recipient pool are discussed in the context of the recombinant erythropoietin era.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
